Domain Therapeutics, a Strasbourg, France- and Montreal, Canada-based biopharmaceutical company dedicated to altering course of Parkinson’s disease, received a second grant of $230k from The Michael J. Fox Foundation (MJFF).
The grant will support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program. The same MJFF supported the initial stages of the program in 2012 through a $300k grant.
Led by Pascal Neuville, CEO, Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G protein-coupled receptors (GPCRs), one of the most important classes of drug targets.
The company discovered that mGluR3 PAMs demonstrate, in vitro, a neuroprotective effect, mediated by the production of growth factors. Stimulating the production of these growth factors is essential for the survival of neurons. Throughout the rest of this year, Domain will identify the most favourable among its mGluR3 PAM leads in order to conduct proof-of-concept studies in Parkinson’s disease models.